Goldman Sachs Group Inc Mei Pharma, Inc. Transaction History

Goldman Sachs Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 May 14, 2024	BUY	$0.22 - $8.4 $1,373 - $52,458	6,245 Added 41.95%	21,132 $5,000
Q4 2022 Feb 13, 2023	BUY	$0.22 - $8.4 $1,373 - $52,458	6,245 Added 41.95%	21,132 $5,000
Q3 2022 May 14, 2024	SELL	$0.41 - $8.8 $40,686 - $873,268	-99,235 Reduced 86.96%	14,887 $6,000
Q3 2022 Nov 10, 2022	SELL	$0.41 - $8.8 $40,686 - $873,268	-99,235 Reduced 86.96%	14,887 $0
Q2 2022 May 14, 2024	BUY	$0.42 - $0.65 $47,931 - $74,179	114,122 New	114,122 $69,000
Q2 2022 Aug 15, 2022	SELL	$0.42 - $0.65 $59,418 - $91,956	-141,472 Reduced 55.35%	114,122 $69,000
Q1 2022 May 16, 2022	BUY	$0.54 - $2.74 $11,241 - $57,041	20,818 Added 8.87%	255,594 $154,000
Q4 2021 Feb 14, 2022	SELL	$2.33 - $3.37 $129,140 - $186,782	-55,425 Reduced 19.1%	234,776 $627,000
Q3 2021 Nov 10, 2021	BUY	$2.52 - $2.99 $731,306 - $867,700	290,201 New	290,201 $801,000

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $385M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.